



COVID-19 and Global Chronic Disease

Guest Editor:

Dr. Ian James Martins

Sarich Neuroscience Research
Institute, Edith Cowan University,
Nedlands 6009, Australia

Deadline for manuscript
submissions:

closed (15 December 2021)

Message from the Guest Editor

Dear Colleagues,

The World Health Organization was informed by Chinese authorities of an outbreak of a novel strain of coronavirus called SARS-CoV-2. The infected individuals may experience mild illness and recover while others can become seriously ill and die. Chronic diseases such as obesity, diabetes, and neurodegenerative diseases are expected to increase in the next 30 years and non-alcoholic fatty liver disease (NAFLD) to reach between 30–40% of the global population. These chronic diseases are associated with an altered immune system that leads to severe illnesses after virus infections. In the developing world, the major concern with COVID-19 infection is that it may lead to multiple organ disease syndrome and the severity of COVID-19 in these individuals may be associated with gene inactivation and linked to programmed cell death. The role of diet, nutrition, and appetite control may be critical to stabilize the immune system and reverse the severity of the disease connected to the global chronic disease epidemic.

In 2021, we would like to publish various articles as indicated in the research field.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

Contact Us

Diseases Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/diseases
diseases@mdpi.com
X@Diseases_MDPI